Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Common sites include the abdomen (at least 2 inches from the belly button), upper thighs, or the back of the upper arm
Both medications are available in New Zealand: Neither medication is funded by Pharmac for weight loss, so both are private-pay only
Key Players in the Obesity GLP-1 Market Novo Nordisk Eli Lilly and Company Amgen BoehringerIngelheim AstraZeneca Pfizer Roche Viking Therapeutics Structure Therapeutics Zealand Pharma Scope of the Report Obesity GLP-1 Market by Segments By Molecule Class: Semaglutide Tirzepatide Other GLP-1 Receptor Agonists By Route of Administration: Injectables Oral Formulations By Payer Type: Public Coverage Private Insurance and Self-Pay By Use-Case Framing: Weight Management Cardiovascular Risk Anchored By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Netherlands Rest of Europe East Asia China Japan South Korea South Asia and Pacific India Australia New Zealand Frequently Asked Questions How big is the obesity GLP-1 market in 2025
If necessary, you can store unused Wegovy at room temperature (59F86F) for up to 28 days
However, their impact goes beyond the number on the scale
Urbanski said she sees the positive impact of communication between healthcare professionals and people living with diabetes, as discussions about lifestyle, work, and environmental factors help to inform nutrition and lifestyle management strategies
US$ 22.67
US$ 26.91
US$ 22.34
US$ 26.95
US$ 20.96
